Literature DB >> 27167921

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats.

Jennifer Altomonte1, Kim A Muñoz-Álvarez2, Katsunori Shinozaki3, Christine Baumgartner4, Georgios Kaissis5, Rickmer Braren5, Oliver Ebert6.   

Abstract

Hepatocellular carcinoma (HCC) is a disease with limited treatment options and poor prognosis. In recent years, oncolytic virotherapies have proven themselves to be potentially powerful tools to fight malignancy. Due to the unique dual blood supply in the liver, it is possible to apply therapies locally to orthotopic liver tumors, which are predominantly fed by arterial blood flow. We have previously demonstrated that hepatic arterial delivery of oncolytic viruses results in safe and efficient transduction efficiency of multifocal HCC lesions, resulting in significant prolongation of survival in immune competent rats. This procedure closely mimics the application of transarterial embolization in patients, which is the standard palliative care provided to many HCC patients. The ability to administer tumor therapies through the hepatic artery in rats allows for a highly sophisticated preclinical model for evaluating novel viral vectors under development. Here we describe the detailed protocol for microdissection of the hepatic artery for infusion of oncolytic virus vectors to treat orthotopic HCC.

Entities:  

Mesh:

Year:  2016        PMID: 27167921      PMCID: PMC4941927          DOI: 10.3791/53757

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  11 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV.

Authors:  Katsunori Shinozaki; Oliver Ebert; Savio L C Woo
Journal:  Hepatology       Date:  2005-01       Impact factor: 17.425

3.  The blood supply of neoplasms in the liver.

Authors:  C BREEDIS; G YOUNG
Journal:  Am J Pathol       Date:  1954 Sep-Oct       Impact factor: 4.307

4.  Evidence-based health policy--lessons from the Global Burden of Disease Study.

Authors:  C J Murray; A D Lopez
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

Review 5.  Pathologic characteristics of hepatocellular carcinoma.

Authors:  T Nakashima; M Kojiro
Journal:  Semin Liver Dis       Date:  1986-08       Impact factor: 6.115

Review 6.  Chemoembolization for hepatocellular carcinoma.

Authors:  Jordi Bruix; Margarita Sala; Josep M Llovet
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus.

Authors:  Katsunori Shinozaki; Oliver Ebert; Chryssanthi Kournioti; Yun-Sheng Tai; Savio L C Woo
Journal:  Mol Ther       Date:  2004-03       Impact factor: 11.454

8.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Authors:  Jeong Heo; Tony Reid; Leyo Ruo; Caroline J Breitbach; Steven Rose; Mark Bloomston; Mong Cho; Ho Yeong Lim; Hyun Cheol Chung; Chang Won Kim; James Burke; Riccardo Lencioni; Theresa Hickman; Anne Moon; Yeon Sook Lee; Mi Kyeong Kim; Manijeh Daneshmand; Kara Dubois; Lara Longpre; Minhtran Ngo; Cliona Rooney; John C Bell; Byung-Geon Rhee; Richard Patt; Tae-Ho Hwang; David H Kirn
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

9.  Engineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma.

Authors:  Jennifer Altomonte; Sabrina Marozin; Roland M Schmid; Oliver Ebert
Journal:  Mol Ther       Date:  2009-10-06       Impact factor: 11.454

10.  Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats.

Authors:  Jennifer Altomonte; Rickmer Braren; Stephan Schulz; Sabrina Marozin; Ernst J Rummeny; Roland M Schmid; Oliver Ebert
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more
  1 in total

1.  A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.

Authors:  Sarah Abdullahi; Melanie Jäkel; Sabine J Behrend; Katja Steiger; Geoffrey Topping; Teresa Krabbe; Alessio Colombo; Volker Sandig; Tobias S Schiergens; Wolfgang E Thasler; Jens Werner; Stefan F Lichtenthaler; Roland M Schmid; Oliver Ebert; Jennifer Altomonte
Journal:  J Virol       Date:  2018-11-12       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.